Non-small-cell lung cancer (NSCLC) is the most prevalent form of lung cancer and has a poor five-year survival rate of 15%. Chemotherapy and targeted therapies have significantly improved patients’ prognosis. Nevertheless, after a successful initial response, some patients relapse when cancer cells become resistant to drug treatments, representing an important clinical limitation. Therefore, investigating the mechanisms of drug resistance is of significant importance. Recently, considerable attention has been given to long non-coding RNAs (lncRNAs), a heterogeneous class of regulatory molecules that play essential roles in tumorigenesis by modulating genes and signalling pathways involved in cell growth, metastasis and drug response. In this article, we review recent research findings on the role of lncRNAs in drug resistance in NSCLC, highlighting their mechanisms of action.

非小细胞肺癌 (NSCLC) 是最普遍的肺癌形式，其五年生存率较差，仅为 15%。化疗和靶向治疗显着改善了患者的预后。然而，在成功的初始反应后，当癌细胞对药物治疗产生耐药性时，一些患者会复发，这是一个重要的临床限制。因此，研究耐药机制具有重要意义。最近，长链非编码 RNA (lncRNA) 受到了相当多的关注，lncRNA 是一类异质的调节分子，通过调节参与细胞生长、转移和药物反应的基因和信号通路在肿瘤发生中发挥重要作用。在本文中，我们回顾了最近关于 lncRNA 在 NSCLC 耐药中的作用的研究结果，